A DBI, or Drug Burden Index, is a clinical scoring tool that measures how much a person’s medications are loading their body with anticholinergic and sedative effects. A score of 0 means none of your medications carry these effects, while a score of 1.0 or higher signals a very high drug burden linked to falls, cognitive decline, and reduced physical function. The tool is primarily used in older adults, where multiple medications with these properties often overlap and compound each other’s side effects.
What the DBI Actually Measures
Many common medications carry side effects that either block a chemical messenger called acetylcholine (anticholinergic effects) or slow down brain activity (sedative effects). Individually, these effects might be mild. But older adults often take several of these medications at once, and the combined load can quietly erode thinking ability, balance, and independence.
The DBI captures this cumulative burden in a single number. It factors in every anticholinergic and sedative medication a person takes, weighted by dose. A higher dose of a given drug contributes more to the score than a lower dose, which makes the DBI more nuanced than tools that simply count how many risky medications someone is on. One validated list used in DBI assessments includes 258 medications: 117 classified as anticholinergic and 141 as sedative.
Which Medications Count
The range of drugs that contribute to a DBI score is broader than most people expect. It’s not limited to sleeping pills or obvious sedatives. In one large study of medication use, the most common contributors to DBI scores were:
- Antipsychotics (the single largest contributor, making up nearly 50% of flagged medications in psychiatric settings)
- Antiepileptic drugs used for seizures, nerve pain, and mood stabilization
- Antidepressants, particularly older types with stronger anticholinergic activity
- Antihistamines, including common allergy and sleep medications
- Benzodiazepines, prescribed for anxiety and insomnia
- Diuretics (water pills) used for blood pressure and heart failure
- Sleep aids like zopiclone and similar hypnotics
Some of these, like over-the-counter antihistamines, are medications people take without thinking twice. Others, like certain blood pressure drugs or bladder medications, carry anticholinergic effects that aren’t obvious from the label. That hidden overlap is exactly what the DBI is designed to catch.
How DBI Scores Are Categorized
Researchers and clinicians break DBI scores into five risk tiers:
- 0 (reference): No anticholinergic or sedative drug burden
- Above 0 but below 0.20 (low): Minimal exposure
- 0.20 to below 0.50 (moderate): Notable cumulative burden
- 0.50 to below 1.0 (high): Significant risk for adverse effects
- 1.0 or above (very high): Strongest association with falls and functional decline
These thresholds help clinicians prioritize which patients need the most urgent medication review. Someone with a DBI of 1.2, for instance, is carrying a drug burden that warrants a close look at whether every contributing medication is still necessary.
Health Risks Tied to Higher Scores
A systematic review examining the link between DBI scores and patient outcomes found consistent patterns. Of 14 studies examining falls, 11 (about 71%) found that a higher DBI was significantly associated with more falls. Roughly 55% of studies looking at physical function found meaningful declines in people with elevated scores, and a similar proportion found worse cognitive performance.
A separate long-term study of community-dwelling adults aged 70 to 79 found that in years when participants had higher DBI scores, they also had significantly lower scores on tests of global cognition and processing speed. The association grew stronger with each passing year of the study, suggesting that sustained drug burden takes a progressively greater toll on mental sharpness. The link between high DBI scores and mortality, hospitalization, or quality of life was less consistent across studies, but the connection to falls, thinking problems, and physical decline held up repeatedly.
How DBI Differs From Other Screening Tools
The DBI isn’t the only tool for flagging risky medications in older adults. The Anticholinergic Risk Scale (ARS) and the Anticholinergic Cognitive Burden (ACB) scale are also widely used. The key difference is scope: those tools focus specifically on anticholinergic medications, while the DBI captures sedative drugs as well. That broader lens matters because sedatives like opioids, benzodiazepines, and sleep aids are among the most common contributors to falls and confusion in older people.
The DBI also accounts for dose, which most anticholinergic-only scales do not. Two people taking the same medication at different doses will get different DBI contributions from that drug. This dose-sensitivity makes the DBI particularly useful for spotting situations where a simple dose reduction, rather than stopping a medication entirely, could meaningfully lower someone’s risk.
How Clinicians Use the DBI in Practice
In hospitals and aged care settings, DBI scores are increasingly being built into electronic medical records so pharmacists can see them at a glance. One pilot program integrated DBI scores directly into the pharmacy patient list, allowing pharmacists to sort patients by score and prioritize those with the highest burden for medication review. A dedicated pharmacist then reviewed each flagged patient’s full medication list, identified drugs that could potentially be reduced or stopped, and discussed specific recommendations with the treating doctor.
The results were meaningful. Before the program, about 31% of patients had at least one anticholinergic or sedative medication reduced or stopped during their hospital stay. After the DBI-guided intervention, that rose to 43%. Opioid deprescribing saw the most dramatic change, jumping from about 18% to 46% of opioid prescriptions being stopped or dose-reduced. Notably, having the pharmacist actively discuss recommendations with doctors was what drove the improvement. Simply displaying the DBI score in the medical record, without that conversation, wasn’t enough to change prescribing behavior.
For individuals, a DBI review typically happens during a comprehensive medication review, often triggered by a fall, a hospital admission, or a noticeable decline in memory or mobility. The goal isn’t to stop all flagged medications. Many of them serve important purposes. Instead, it’s about finding the ones where the benefit no longer outweighs the cumulative burden, and gradually tapering them under medical supervision.